This is unpublished


Infectious Diseases
Professor, Department of Laboratory Medicine & Pathology
Professor, Department of Medicine
Member, Division of Vaccine & Infectious Disease (VIDD), Clinical Research, & Public Health Sciences
President & Director Emeritus, Fred Hutchinson Cancer Research Center

related links


Dr. Corey's laboratory currently focuses on the immunobiology of HSV-2 infections. He's had a longstanding interest in this area, having had continuous NIH funding since 1978. This program involves clinical investigations of HSV reactivation and transmission, laboratory based studies on the cellular immunology of HSV, and characterization of HSV-HIV interactions. In the last few years, the laboratory has focused on developing an HSV vaccine by defining the T-cell responses to HSV, especially cytotoxic T-cell responses as a means of developing CTL-based vaccines for immunotherapy or prophylaxis of genital HSV. The laboratory has focused on tissue resident T cells and uses a number of recently developed technologies to investigate in situ immune responses to HSV reactivation. These technologies are also adapted to studies of HIV cure. Drs. Jia Zhu, research assistant professor; Dr. David Koelle, professor of Medicine; Keith Jerome, professor of Laboratory Medicine and head of the Diagnostic Virology Division; and Christine Posavad, senior principal research scientist are involved in the laboratory programs. The Clinical Research Program in genital herpes is directed by Dr. Anna Wald, professor of Medicine and Dr. Christine Johnston, assistant professor of Medicine. Dr. Wald is medical director of the Virology Research Clinic, a specialty clinic dedicated to a wide range of clinical studies on HSV infection, including resolution frequency, vaccine efficacy and technology development.

Most recently, the laboratory has been involved with defining the mechanisms by which chimeric antigen receptor T cells (CAR T cells) kill tumor and HIV targets in vivo. These studies are done in collaboration with investigators in tumor immunity and transplant biology at the Fred Hutch.

Dr. Corey is co-PI of the NIAID supported HIV Vaccine Trials Network (HVTN), a global network of clinical trial sites and laboratories dedicated to phase I-III trials of candidate HIV vaccines and other preventative and treatment options. Candidates interested in developing a career in HIV vaccines are available for mentorship by Dr. Corey.

Training opportunities for postdoctoral fellows interested in learning vaccine biology and clinical trial research are available.

research interests

  • Herpes simplex virus type 2 (HSV-2) pathogenesis and the host immune response
  • Immunotherapeutic approaches to viral infections and cancer
  • HIV and herpesvirus vaccine development

education & training

MD, University of Michigan Medical School, Ann Arbor, MI (1971)

Intern, University of Michigan Medical Center Hospitals, Ann Arbor, MI (1971-1972)

Junior Assistant Resident, University of Michigan Medical Center Hospitals, Ann Arbor, MI (1972-1973)

Epidemic Intelligence Service Officer, Respiratory and Special Pathogens Branch, Viral Diseases Division, Centers for Disease Control, Atlanta, GA (1973-1975)

Senior Fellow, Division of Infectious Disease, University of Washington, Seattle, WA (1975-1977)


Phi Beta Kappa

Thomas Parran Lifetime Achievement Award, American STD Association

Distinguished Alumnus Award, University of Michigan Medical School

Elected, Institute of Medicine, National Academy of Medicine

Named one of the Top 400 Highly Influential Biomedical Researchers worldwide,1996-2011



Posavad CM, Zhao L, Mueller DE, Stevens CE, Huang ML, Wald A, Corey L. Persistence of mucosal T cell responses to herpes simplex virus type 2 (HSV-2) in the female genital tract. Mucosal Immun. 2015 Jan;8(1):115-26.
• PubMed Abstract

Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, Klock A, Jin L, Diem K, Koelle DM, Wald A, Robins H, Corey L. Immune surveillance by CD8aa+ skin-resident T cells in human herpes virus infection. Nature. 2013 May 23;497(7450):494-7.
• PubMed Abstract

Peng T, Zhu J, Phasouk K, Koelle D, Wald A and Corey L. An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of HSV-2 infection. J Virol. 2012 Oct;86(19):10587-96.
• PubMed Abstract

Gray GE, Allen M, Moodie Z, Churchyard G, Bekker, L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG, on behalf of the HVTN 503/Phambili study team. Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomized, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11(7): 507-15.
• PubMed Abstract

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci USA. 2010;107(44): 18973-8.
• PubMed Abstract

Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007; 204(3): 595-603. 
• PubMed Abstract